---
title: "Onconetix, Inc. (ONCO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ONCO.US.md"
symbol: "ONCO.US"
name: "Onconetix, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T14:02:15.177Z"
locales:
  - [en](https://longbridge.com/en/quote/ONCO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ONCO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ONCO.US.md)
---

# Onconetix, Inc. (ONCO.US)

## Company Overview

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.onconetix.com](https://www.onconetix.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.69)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 328 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -61.81% |  |
| Net Profit YoY | 82.19% |  |
| P/B Ratio | 0.02 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 211827.78 |  |
| Revenue | 735198.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -127.45% | E |
| Profit Margin | -1319.55% | E |
| Gross Margin | -7.71% | E |
| Revenue YoY | -61.81% | E |
| Net Profit YoY | 82.19% | A |
| Total Assets YoY | -21.00% | E |
| Net Assets YoY | 194.19% | A |
| Cash Flow Margin | 97.71% | C |
| OCF YoY | -61.81% | E |
| Turnover | 0.04 | E |
| Gearing Ratio | 20.80% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Onconetix, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-61.81%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "82.19%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.02",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "211827.78",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "735198.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-127.45%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1319.55%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-7.71%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-61.81%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "82.19%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-21.00%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "194.19%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "97.71%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-61.81%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.04",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.80%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.02 | 70/386 | - | - | - |
| PB | 0.02 | 2/386 | 0.82 | 0.62 | 0.13 |
| PS (TTM) | 0.29 | 7/386 | 3.42 | 1.82 | 0.84 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ONCO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ONCO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ONCO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ONCO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**